Provided by Tiger Trade Technology Pte. Ltd.

CALCIMEDICA

1.92
-0.0500-2.54%
Post-market: 1.91-0.0100-0.52%19:30 EDT
Volume:60.24K
Turnover:116.69K
Market Cap:13.11M
PE:-0.29
High:2.00
Open:1.98
Low:1.92
Close:1.97
52wk High:36.00
52wk Low:1.87
Shares:6.83M
Float Shares:3.96M
Volume Ratio:0.87
T/O Rate:1.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.6528
EPS(LYR):-9.8500
ROE:-365.70%
ROA:-63.58%
PB:2.38
PE(LYR):-0.19

Loading ...

CalciMedica, FDA alignment de-risks regulatory path, says H.C. Wainwright

TIPRANKS
·
Jul 29

CalciMedica Reaches FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis

MT Newswires Live
·
Jul 29

CalciMedica - Expects Ind Submission for Cm5480 in Mid-2027

THOMSON REUTERS
·
Jul 29

CalciMedica Announces FDA Alignment on Phase 2B Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints

THOMSON REUTERS
·
Jul 29

CalciMedica - Plans Phase 1B Trial for Auxora in Pah with Data Expected Mid-2027

THOMSON REUTERS
·
Jul 29

CalciMedica Inc: Continues to Advance Preparations for Phase 2B Trial

THOMSON REUTERS
·
Jul 29

CalciMedica - FDA Aligns on Phase 2B Primary Endpoint of New-Onset Severe Respiratory Failure

THOMSON REUTERS
·
Jul 29

Calcimedica - Prospectus Covers Resale of up to 56,020,287 Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
Jul 25

Calcimedica Announces Annual Shareholder Meeting

Reuters
·
Jul 14

Calcimedica Files Initial Beneficial Ownership Statement for Alafi Capital Co LLC

Reuters
·
Jul 11

Calcimedica Files Form 3 Initial Beneficial Ownership Statement for Director Evgeny Zaytsev

Reuters
·
Jul 08

CalciMedica Announces Board Expansion and Leadership Transition

TIPRANKS
·
Jul 08

Calcimedica Names Evgeny Zaytsev to Board as Director Expands to Eight Members

Reuters
·
Jul 08

Calcimedica Director Fred A. Middleton Acquires 248,972 Common Shares Worth $200,000

Reuters
·
Jun 29

CalciMedica Advances Auxora After Favorable FDA Safety Review

TIPRANKS
·
Jun 25

Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and CalciMedica (CALC)

TIPRANKS
·
Jun 25

CalciMedica Says Auxora Phase 2 Trial May Continue Dosing After FDA Review

MT Newswires Live
·
Jun 24

CalciMedica Amends Loan, Issues New Equity Warrants

TIPRANKS
·
Jun 24

CalciMedica announces $49M private placement

TIPRANKS
·
Jun 24

Calcimedica - Proceeds to Support Phase 1B Auxora Study in Pah and Cm5480 Ind Clearance, Data Expected Mid-2027

THOMSON REUTERS
·
Jun 24